ClinicalTrials.gg
RecruitingNCT03101995Updated May 28, 2025

Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease

A Phase 2 interventional study of Gemcitabine in Cervical Cancer, sponsored by National Institute of Cancerología. Recruiting at 1 site in Mexico. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by National Institute of Cancerología · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2018; still recruiting 8 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing gemcitabine in Uterine Cervical Neoplasms — 4 open to participants now, 4 under way, 3 of them phase 3. Gemcitabine · Uterine Cervical Neoplasms.

Planned enrollment
13th of 16
18 · median 95
Started
2018
with 1 other
Phase 2
6 of 18
1 open now
Registered
14th of 18
by date
Lead sponsor
2 of 18
National Institute of Cancerología

Among the 18 studies testing gemcitabine in Uterine Cervical Neoplasms, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 in phase 2, and was the 14th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

4 of the 18 studies testing gemcitabine in Uterine Cervical Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing gemcitabine in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

From the global burden of Cervical Cancer (CC), 85% occurs in developing countries, representing 12% of cancer in women. In Mexico CC ranks second in incidence and mortality among women. The National Institute of Cancer in Mexico (lNCAN) receives annually about 500 patients with CC, 80% of which are diagnosed with locally advanced disease. Furthermore, 10 to 20% of these present kidney deterioration. The main reason for kidney disease is ureteral obstruction, other causes include age and comorbidities, such as diabetes and hypertension. The standard treatment for locally advanced disease consists in concomitant chemo-radiotherapy based on cisplatin (QT-RT), followed by brachytherapy, with an absolute benefit of 10%. However, the use of cisplatin in patients with renal disease may be questionable, considering it is a nephrotoxic treatment. Given that renal dysfunction limits the standard treatment efficiency because of the widely known nephrotoxicity of cisplatin, in most Cancer Centers of our country, patients with renal dysfunction receive only radiation therapy, even though it has proven less effective than concomitant QT-RT, limiting disease-free and overall survival of these patients. Venook et al. used gemcitabine as a radiosensitizer in patients with cancer and renal dysfunction. Our group, has observed encouraging results using gemcitabine as an alternative to cisplatin in concomitant treatment with radiotherapy, in CC patients with renal insufficiency. 89% of patients had complete response and improvement in renal function, with an enhanced creatinine clearance after treatment. Therefore, it is necessary to explore the safety of gemcitabine as an alternative treatment for CC patients with locally advanced disease and renal deterioration. We propose this clinical trial to assess the safety of treatment with gemcitabine and specifically on renal function in patients with renal deterioration. It is important to take into consideration that CC in advanced stages produces pain, transvaginal fetid discharge and general discomfort. It also causes side effects secondary to renal failure such as nausea, vomiting, fatigue, anemia, among others. These effects have a significant impact on the quality of life of these patients. Cancer treatment and its side effects, besides the implications of a nephrostomy catheter or ileostomy bag, determine the deterioration in the quality of life of the patient, during and sometimes after treatment. Thus it is of utmost importance to evaluate the factors that could help improve the quality of life of patients and explore the factors that deteriorate it. This clinical trial aims to generate scientific evidence to help make the best decisions concerning the treatment of patients with cervical cancer and renal impairment, and the impact on their quality of life.

Read the detailed description

In Mexico, cervical cancer (CC) is the second most frequent cause of death among women, with a mortality rate of 4000 women/year. Concerning the treatment of these patients, there is evidence about the benefit of addition of chemotherapy to radiotherapy in patients with locally advanced CC, with an absolute benefit of 10% in overall survival and a significant reduction in local recurrence. Cisplatin is currently the standard treatment for CC. Evidence supports that the benefit of chemotherapy is achieved in those patients who receive at least 3 cycles of cisplatin at a dosage of 40mg/m2 weekly. The side effects of cisplatin include nephrotoxicity, neurotoxicity, nausea and vomiting, ototoxicity, electrolyte disturbance, and hemolytic anemia. For this reason, the choice of using cisplatin as a radiosensitizer requires careful consideration of the renal function of the patient, prior to the initiation of treatment. The glomerular filtration rate deteriorates with age and many patients have comorbid medical illnesses that further compromise the kidney. Gemcitabine has been tested as a single agent in CC for its radiosensitizing properties. Clinical profit has been reported along with reasonable tolerance to gemcitabine during radiotherapy. So it can be considered a good alternative treatment for the management of patients with ureteral obstruction and possible renal failure. Even though gemcitabine is well tolerated, the dosage for these patients should be considered with caution, since a specific dosage has not yet been recommended for cancer patients with renal dysfunction.

Our aim is to evaluate the safety of chemo-radiotherapy (QT-RT) concomitant with gemcitabine in patients with locally advanced cervical cancer IB2-IVA and renal deterioration. Our particular objectives are the following:

  1. Evaluate the renal function before, during and after treatment with QT-RT concomitant with gemcitabine.
  2. Assess the safety of concomitant QT-RT with gemcitabine, according to the common toxicity criteria in CTCEA v4.0.
  3. Determine the objective and clinical response rate after treatment with QT-RT concomitant with gemcitabine.
  4. Determine the incidence of percutaneous nephrostomy procedure.
  5. Evaluate the clinical and cabinet criteria established by the protocol for the application of percutaneous nephrostomy or double J catheter and its impact on renal function.
  6. Evaluate the patients' quality of life.
  7. Determine the frequency of complications during and after treatment with QT-RT concomitant with gemcitabine.

Our aim is based on the following hypothesis. Patients with locally advanced CC IB2-IVA and renal dysfunction, that receive concomitant QT-RT with gemcitabine, tolerate the combination with a glomerular filtration rate of >60ml/min/1.73m2, show limited toxicity (Grade l-lll) and a response rate of at least 70%.

Methods.

Study design. It is a Phase II clinical trial, open, single-arm, national, nonrandomized, single-center; to evaluate the safety of gemcitabine in patients with locally advanced CC (IB2-IVA) and renal dysfunction, referring to the National Institute of Cancer in Mexico (INCAN). 18 patients will be included, with cervical malignant tumors of epithelial origin in the neck of the uterus, with renal impairment; candidates for QT-RT. Recruitment of patients will be performed in the first 12 months, with a follow up of 12 months, including 3 patients per month, to complete the total sample in one year (2017-2018).

Treatment. Based on treatment evidence the best dosage of gemcitabine in patients with adequate renal function is 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks, starting in the first week of radiotherapy or as soon as the blood count has recovered after blood transfusion. In our study design, patients will receive concomitant radiotherapy using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks. Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy. In case retroperitoneal or para-aortic lymphnodes appear, patients will be treated with extended fields of radiotherapy at conventional doses. Dose will be adjusted up to 75% of the complete dosage in case of grade 3 (G3) leucopenia, G3 neutropenia, G3 thrombocytopenia, G3 diarrhea, radioepithelitis, or other G3 non hematological toxicity.

In case toxicity is not resolved within a week, treatment application may be delayed up to two weeks. If toxicity persists, subsequent doses will be suspended and the patient will receive only radiation therapy. Acute toxicity will be evaluated according to CTCAE (v. 4.03) toxicity criteria. When possible, chemotherapy treatment will coincide with radiotherapy. We will make every reasonable effort to ensure that radiotherapy treatment continues without interruption. Use of colony stimulating factor is allowed at the discretion of the researcher, it should not be administered within 24 hours prior or after treatment with chemotherapy. During each cycle, in all cases, creatinine clearance will be measured.

When an anaphylaxis or hypersensitivity reaction is suspected, gemcitabine infusion will be immediately stopped and replaced by saline solution. A physical examination including vital signs will be performed every 15 minutes, until the the patient's condition improves. Airways will be kept free. If a local reaction occurs (hives and angioneurotic edema), epinephrine and diphenhydramine should be administered. In case of bronchospasm, epinephrine, diphenhydramine, hydrocortisone, methylprednisolone and oxygen will be administered. In case of fever, antipyretic maneuvers will be performed and if the patient presents trembling, dipyrone will be administered. Emergency treatment will be evaluated and individualized by the immediate attention medic, who will administer the treatment that he deems pertinent to stabilize the patient.

The administration of other drugs will be performed if the physician considers it appropriate, however patients will not receive any other anti-cancer therapy under research, while participating in this study.

Sample size calculation. A sample space of 18 patients will be included if prior consent is acquired and if they meet the inclusion criteria.

This study will consider patient replacement in the following situation: if an adverse event occurs that prevents the patient to start the treatment previously described in the protocol after she has signed the informed consent.

Statistical analysis. A univariate analysis will be performed to describe the study population. Descriptive statistics will be used to obtain measures of central tendency and dispersion, as well as frequency of distribution for qualitative variables. A Bivariate analysis will be performed to observe the influence among variables. Kruskal-Walliss test will be used to evaluate variables of interest for different time points, before, during and after treatment. To assess differences in clinical response, we will use Zarah Fisher's exact test for categorical variables, and Mann-Whitney U test for quantitative variables. All confidence intervals will be constructed with a confidence of 95% (α=0.05). The interpretation of the study results will be responsibility of researchers. An interim analysis and a final report are planned; the first analysis will be made once the first 17 patients are included, and the final analysis is planned at 12 months after the last patient is included. Data processing and analysis will be performed with the SPSS package (version 19.0®) for Microsoft.

Safety analysis. Safety will be assessed in all patients who have received at least one chemotherapy application. To determine the safety of gemcitabine the following will be evaluated: to assess the safety of renal function, glomerular filtration rate will be evaluated; to assess systemic safety, number of required blood transfusions, clinical adverse events (including laboratory abnormalities), severity of each adverse event according to the toxicity criteria of CTCEA version 4.0, complications presented, and chronic toxicity according to RTOG criteria (Acute Radiation Morbidity Scoring Criteria). These will be evaluated 3 months after completing concomitant QT/RT treatment, in follow-up visits.

Procedures.

  • Patients inclusion. Patients may start treatment within 21 days after being enrolled in the study. During the first seven days prior to the inclusion of the patients in the study, clinical history, complete physical examination including vital signs, weight, and general condition according to the ECOG scale, will be performed. Laboratory data (hematic biometry, serum electrolytes, glucose, serum creatinine, BUN, arterial blood gas, liver function enzymes, general urine test, urine culture, creatinine clearance in 24 hours, pregnancy test and HIV), will be measured within the first 14 days, prior to inclusion. Serum Cystatin C and urine albumin will also be determined at the National Institute of Cardiology in Mexico, within 21 days prior to inclusion. Imaging studies (PET-CT) will be performed to assess the tumor. To evaluate renal function, a bilateral renal ultrasound and a renal gammagraphy will be performed within 28 days prior to inclusion in the study. Additionally, thorax radiography will be required. If the patient presents hydronephrosis G3-4, a double J stent will be used for continent diversion, or a percutaneous nephrostomy procedure, and the patient may start treatment within the first 24-48 hours. Patients who meet the selection criteria will be included in the study to start treatment. Before initiating QT-RT, quality of life questionnaires will be applied. To have a more accurate nephrological examination, the results of all the laboratory tests previously mentioned for each patient, will be initially evaluated by nephrologists from the National Institute of Cardiology and the National Institute of Nutrition in Mexico.
  • Visits during the study. After signing the informed consent, the patient will be informed when she will begin participating in the study (screening visit). If the patient complies with the inclusion criteria, a total of 21 visits will be scheduled. Of these, 8 visits will be given during treatment (an initial visit, 6 visits for QT-RT, 2 to 5 visits for brachytherapy), and 8 follow-up visits.
  • Monitoring. Patient visits after QT-RT will be every 3 months during the follow-up year. Laboratory tests will be performed every visit (hematic biometry, serum electrolytes, glucose, serum creatinine, BUN, liver function enzymes, and general urine test). In case of clinical suspicion of progression, image studies (PET-CT), bilateral renal ultrasound and creatinine clearance calculation will be requested. The information obtained during this period will be limited physical examination, performance status assessment (ECOG), weight, measurement of tumor lesions by imaging studies, and date of progression or recurrence. Late adverse events will be evaluated at each scheduled visit. EORTC QLQ-30 and QLQ Cx-24 questionnaires will be applied during follow-up every 3 months for the first two years, and every 6 months for the following 3 years.
  • Sample collection. No tissue or additional blood samples will be obtained, other than the blood samples used as part of the routine clinical laboratory tests.
  • Informed consent acquisition. In the first visit, the consent will be read and explained to the patient, clarifying the risks and benefits involved in the study. Two witnesses, independent from the study, will be present when the consent is read and explained to the patient. The patient will have the choice to not participate or withdraw from the study at any time, her decision will not affect the quality of care and treatment that the attending physician will provide. The researcher will be governed by the ethical principles established in the Helsinki Accord. The physician will adequately respond all the matters of interest to the patient.

Ethical considerations. The Research Committee and the Ethics Committee of the National Institute of Cancer in Mexico has approved the protocol and the informed consent document. The approval will be valid for one year with the possibility of re-approval. Authorization from the national regulatory authority, the Federal Commission for the Protection against Health Hazards (COFEPRIS), will be requested.

Patients participating in this study will be informed, through the informed consent, of all the details concerning this trial. The patients who agree to participate in the trial will express their willingness by signing the informed consent document, being clarified that they can leave the trial at any time, if they wish to do so.

Regulatory considerations. This study abides by the ethical principles established by the international community, in accordance to the Good Clinical Practices, the Nüremberg Code, the Helsinki Accord, the Statement of Compliance with International Conference on Harmonization Guidelines for Good Clinical Practice, and the Regulations of the General Law of Health in the matter of research for health.

03

Conditions studied

  • Cervical Cancer

Keywords

  • Treatment
  • Locally advanced cervical cancer
  • Renal failure
  • Gemcitabine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who give their written consent to participate in the study.
  2. Women, 18-70 years of age, considering the following criteria:

    • In women of childbearing age: i. Negative serum pregnancy test at baseline (14 days prior to the start of -RT).

    ii. The patient must accept the use of any method approved by the attending physician during the study and 12 weeks after the end of treatment.

    • women must meet at least one of the following parameters for eligibility: i. Prior bilateral oophorectomy ii. Age ≥ 60 years iii. Age \< 60 years, with amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal parameters.
  3. Diagnosed with CC IB2-IVA, with or without retroperitoneal lymph nodes (para-aortic), smaller than 2 cm.
  4. With histologic confirmation of squamous carcinoma, adenosquamous carcinoma, adenocarcinoma or glassy cells carcinoma.
  5. Without previous treatment and medically able to receive gemcitabine.
  6. Disease measurable by CT and/or MRI according to (v1.1) criteria.
  7. Functional status of 0-3 according to WHO criteria.
  8. Renal dysfunction defined by glomerular filtration (GF) \<60 ml/min/1.73m2 calculated by the formula.
  9. Normal hematologic and liver function, as defined by the following parameters:

    • > 10g/L. (Transfusion prior to the treatment is allowed to reach this level of hemoglobin).
    • Leucocytes > 4000/mm3.
    • > 100,000/mm3.
    • Total ≤1.5 times the upper normal limit (UNL).
    • Transaminases \< 1.5 times the UNL.
  10. Normal PA chest radiograph.

Exclusion criteria

Exclusion criteria.

  1. Patients with prior or concomitant , except non-melanoma skin carcinoma.
  2. Patients with diabetes and/or hypertension with retinopathy or albuminuria >300.
  3. Patients with evidence of active TB infection.
  4. Patients infected with (HIV).
  5. Patients with a history of Systemic Lupus Erythematosus and other rheumatologic diseases that cause kidney damage.
  6. Patients with vesicovaginal or vesicorectal fistula at the time of diagnosis.
  7. Patients with uncontrolled intercurrent diseases including active infections that contraindicate , symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, decompensated diabetes, difficult control hypertension and psychiatric illness.
  8. Concomitant treatment with other experimental drugs.
  9. Social, family or geographical conditions that suggest a poor adherence to the study.

Study discontinuation criteria.

  1. Evidence of disease progression, if the researcher considers that the patient would benefit more with other therapy.
  2. At the request of the patient.
  3. By unacceptable toxicity.
  4. Pregnancy.

Violation of starting criteria. Criteria must be followed punctually. If a patient were inappropriately included, she must be discontinued from the study.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Gemcitabine

    Gemcitabine doses: 300 mg/m2/week for 6 weeks.

    Drug: Gemcitabine

Interventions

  • Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks. Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks. Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Glomerular Filtration Rate

    Safety of gemcitabine regarding renal function will be assessed through glomerular filtration rate. An improvement of 10 ml/min/1.73m2 as compared to basal glomerular rate is expected by the end of treatment.

    Time frame: During and every 3 months after completing concomitant QT/RT treatment, for the first two years, and every 6 months for the following 3 years.

Secondary outcomes

  1. Toxicity of gemcitabine in patients with carcinoma of cervix and renal disease

    Toxicity will be evaluated according to the toxicity criteria of CTCEA v. 4.03. A toxicity index of \<4 is expected during treatment.

    Time frame: During and every 3 months after completing concomitant QT/RT treatment, for the first two years, and every 6 months for the following 3 years.

07

Study locations

1 of 1 sites recruiting
  • National Institute of Cancer
    Mexico City, DF 14080, Mexico
    Recruiting
08

References and documents

Publications

  • Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6. doi: 10.1016/S0140-6736(01)05965-7. PubMed 11564482 ↗
  • Brown JM. Carbogen and nicotinamide: expectations too high? Radiother Oncol. 1992 Jun;24(2):75-6. doi: 10.1016/0167-8140(92)90281-x. No abstract available. PubMed 1386679 ↗
  • Zarba JJ, Jaremtchuk AV, Gonzalez Jazey P, Keropian M, Castagnino R, Mina C, Arroyo G; GETICS (Grupo de Estudio, Tratamiento e Investigacion del Cancer del Sur) Argentina. A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Ann Oncol. 2003 Aug;14(8):1285-90. doi: 10.1093/annonc/mdg345. PubMed 12881394 ↗
  • Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, Reyes M, Mota A, Munoz D, Solorza G, Hinojosa LM, Guadarrama R, Florentino R, Mohar A, Melendez J, Maldonado V, Chanona J, Robles E, De la Garza J. A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol. 2001 Apr;12(4):541-7. doi: 10.1023/a:1011117617514. PubMed 11398890 ↗
  • Chang PY, Dai MS, Ho CL, Yao NS. Administration of gemcitabine and cisplatin in cancer patients with renal failure under hemodialysis. J BUON. 2013 Oct-Dec;18(4):1058-61. PubMed 24344039 ↗
  • Pattaranutaporn P, Thirapakawong C, Chansilpa Y, Therasakvichya S, Ieumwananontachai N, Thephamongkhol K. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncol. 2001 Jun;81(3):404-7. doi: 10.1006/gyno.2001.6197. PubMed 11371129 ↗
  • Bosch A, Frias Z, Valda GC. Prognostic significance of ureteral obstruction in carcinoma of the cervix uteri. Acta Radiol Ther Phys Biol. 1973 Feb;12(1):47-56. doi: 10.3109/02841867309131091. No abstract available. PubMed 4725645 ↗
  • Cetina L, Rivera L, Candelaria M, de la Garza J, Duenas-Gonzalez A. Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. Anticancer Drugs. 2004 Sep;15(8):761-6. doi: 10.1097/00001813-200409000-00004. PubMed 15494637 ↗
  • Rose PG, Ali S, Whitney CW, Lanciano R, Stehman FB. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 May;117(2):270-5. doi: 10.1016/j.ygyno.2010.01.045. Epub 2010 Feb 24. PubMed 20181381 ↗
  • Tomimaru Y, Eguchi H, Satoh T, Tomokuni A, Asaoka T, Wada H, Marubashi S, Ogawa K, Takehara T, Mori M, Doki Y, Nagano H. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Jpn J Clin Oncol. 2015 Apr;45(4):343-8. doi: 10.1093/jjco/hyu224. Epub 2015 Jan 14. PubMed 25589454 ↗
  • Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul;18(14):2780-7. doi: 10.1200/JCO.2000.18.14.2780. PubMed 10894879 ↗
  • Tanji N, Fukumoto T, Miura N, Yanagihara Y, Shirato A, Azuma K, Miyauchi Y, Kikugawa T, Shimamoto K, Yokoyama M. Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency. Int J Clin Oncol. 2013 Oct;18(5):910-5. doi: 10.1007/s10147-012-0466-9. Epub 2012 Aug 31. PubMed 22936563 ↗
  • Grigsby PW. Cervical cancer: combined modality therapy. Cancer J. 2001 Jul-Aug;7 Suppl 1:S47-50. PubMed 11504285 ↗
  • Zahra MA, Taylor A, Mould G, Coles C, Crawford R, Tan LT. Concurrent weekly cisplatin chemotherapy and radiotherapy in a haemodialysis patient with locally advanced cervix cancer. Clin Oncol (R Coll Radiol). 2008 Feb;20(1):6-11. doi: 10.1016/j.clon.2007.10.007. Epub 2008 Jan 11. PubMed 18191389 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Jul 2025, 89 months after the start.

Of 155 non-industry phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 89 months is above that.

Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2016
First posted
Apr 5, 2017
StartActual
Jan 16, 2018
Primary completionEst.
Jul 1, 2025
CompletionEst.
Nov 1, 2025
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03101995
Lead sponsor
National Institute of Cancerología
Collaborators
Instituto Nacional de Cardiologia Ignacio Chavez, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Responsible party
Lucely Cetina Pérez (MD, Master of Science, National Institute of Cancerología) — Principal investigator
First posted
Apr 5, 2017
Start date
Jan 16, 2018
Primary completion
Jul 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
May 28, 2025

Study contacts

Lucely C Cetina, MD, M.Sc.
Contact
lucelycetina.incan@gmail.com
+5215554851237
Roberto Jiménez, MD, M.Sc.
Contact
jilir@yahoo.com.mx
+5215554851237
Lucely C Cetina, MD, M.Sc.
principal investigator · National Institute of Cancerología

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion